% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jansen:167446,
      author       = {L. Jansen$^*$ and D. Boakye$^*$ and E. Alwers$^*$ and P. R.
                      Carr$^*$ and C. Reissfelder and M. Schneider and U. M.
                      Martens and J. Chang-Claude$^*$ and M. Hoffmeister$^*$ and
                      H. Brenner$^*$},
      title        = {{U}ptake {R}ates of {N}ovel {T}herapies and {S}urvival
                      {A}mong {P}rivately {I}nsured {V}ersus {P}ublicly {I}nsured
                      {P}atients {W}ith {C}olorectal {C}ancer in {G}ermany.},
      journal      = {Journal of the National Comprehensive Cancer Network},
      volume       = {19},
      number       = {4},
      issn         = {1540-1405},
      address      = {Cold Spring Harbor, NY},
      publisher    = {Harborside Press},
      reportid     = {DKFZ-2021-00350},
      pages        = {411-420},
      year         = {2021},
      note         = {#EA:C070#LA:C070# / 19(4):411-420},
      abstract     = {In the era of personalized medicine, cancer care is subject
                      to major changes and innovations. It is unclear, however, to
                      what extent implementation of such innovations and their
                      impact on patient outcomes differ by health insurance type.
                      This study compared provision of treatment and survival
                      outcomes among patients with colorectal cancer (CRC) who had
                      statutory health insurance (SHI) versus private health
                      insurance (PHI) in Germany.We analyzed patterns of CRC
                      treatment (surgery, chemotherapy/radiotherapy, and targeted
                      therapy) and survival in a large cohort of patients who were
                      diagnosed with CRC in 2003 through 2014 and were observed
                      for an average of 6 years. Associations of type of health
                      insurance with treatment administration and with overall,
                      CRC-specific, and recurrence-free survival were investigated
                      using multivariable logistic and Cox proportional hazards
                      models, respectively.Of 3,977 patients with CRC, 427
                      $(11\%)$ had PHI. Although type of health insurance was not
                      associated with treatment administration in patients with
                      stage I-III disease, those with stage IV disease with PHI
                      more often received targeted therapy $(65\%$ vs $40\%;$ odds
                      ratio, 2.43; $95\%$ CI, 1.20-4.91), with differences
                      decreasing over time because of catch-up of uptake rates in
                      patients with SHI. Median overall survival was longer in
                      patients with PHI than in those with SHI (137.0 vs 114.9
                      months; P=.010), but survival advantages were explained to a
                      large extent by differences in sociodemographic factors. In
                      patients with stage IV disease, survival advantages of PHI
                      were nonsignificant and were restricted to the early years
                      after diagnosis.We observed major differences in uptake of
                      targeted therapy between patients with PHI and those with
                      SHI but no differences in patient survival after adjusting
                      for relevant sociodemographic, clinical, and tumor
                      characteristics. Further studies are needed on factors
                      associated with the uptake of therapeutic innovations and
                      their impact on patient survival by health insurance type.},
      cin          = {C070 / C020 / C120 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C020-20160331 /
                      I:(DE-He78)C120-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33578373},
      doi          = {10.6004/jnccn.2020.7636.},
      url          = {https://inrepo02.dkfz.de/record/167446},
}